Company Analysis
Sign in

Revolution Medicines, Inc. (RVMD)

Nasdaq: RVMD · Biological Products, (No Diagnostic Substances) · Redwood City, CA · filing with the SEC since 2016
Full chart Alerts Compare
Grade4.9
◀ Past 3.8● Present 5.4▶ Future 5.1
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

40 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Revolution Medicines, Inc.’s names, not what it holds today.

Patents granted
40
40 utility, 1976 to Dec 31, 2025
Granted in 2025
10
Against 4 in 2024 and 12 in 2023
Applications published
109
33 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry22
Pharmaceuticals8
Analysis of biological materials2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Revolution Medicines, Inc. its own name
named as the applicant on its applications, in US
0 granted
97 published
Revolution Medicines, Inc. its own name
US, as the owner printed on each patent
36 granted
3 published
Warp Drive Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
8 published
Warp Drive Bio, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 11, 202512,465,643Ras inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Sep 9, 202512,409,225Ras inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Sep 2, 202512,403,196Ras inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Aug 12, 202512,384,750Ras inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Jul 22, 202512,365,688Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Apr 22, 202512,280,113Ras inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Mar 25, 202512,258,366Bicyclic heteroaryl compounds and uses thereofOrganic fine chemistryRevolution Medicines, Inc.
Mar 18, 202512,252,497Ras inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Jan 21, 202512,202,845Ras inhibitorsPharmaceuticalsRevolution Medicines, Inc.
Jan 7, 202512,187,746C26-linked rapamycin analogs as mTOR inhibitorsOrganic fine chemistryRevolution Medicines, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388608RAS INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
Dec 25, 20252025/0388598RAS INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
Dec 11, 20252025/0375445METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDERPharmaceuticalsRevolution Medicines, Inc.
Dec 4, 20252025/0368661RAS INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
Nov 27, 20252025/0361245RAS INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
Nov 13, 20252025/0345328METHODS OF TREATING A RAS RELATED DISEASE OR DISORDERPharmaceuticalsRevolution Medicines, Inc.
Oct 16, 20252025/0319187RAS INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
Sep 11, 20252025/0282782PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
Aug 28, 20252025/0269037COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USEOrganic fine chemistryRevolution Medicines, Inc.
Aug 14, 20252025/0255964RAS INHIBITORSOrganic fine chemistryRevolution Medicines, Inc.
What it applied for, 2024 to 2025: Organic fine chemistry 28 · Pharmaceuticals 24 · Analysis of biological materials 2 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RVMD · research, not advice